| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5844449 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2014 | 46 Pages |
Abstract
Anti-inflammatory agents, such as acetyl-salicylic acid (ASA), celecoxib, anti-TNF-α agents, minocycline, curcumin and omega-3 fatty acids, are being investigated for use in mood disorders. Current evidence shows improved outcomes in mood disorder patients when anti-inflammatory agents are used as an adjunct to conventional therapy; however, further research is needed to establish the therapeutic benefit and appropriate dosage.
Keywords
LPScalcium-dependent phospholipase A2ACTHNon-steroidal anti-inflammatory drug (NSAID)COX-1 and COX-2TDOIDOTCAsSSRIscPLA25-HIAAPGE2IBDMDDASANSAIDPAMPsCRH5-Hydroxyindoleacetic acidMAOIsRheumatoid arthritisMajor depressive disordermood disorderbipolar disorderArachidonic acidinflammationOmega-3 polyunsaturated fatty acidsinterferonIFNInflammatory bowel diseaseTryptophan 2,3-dioxygenasetricyclic antidepressantsWorld Health OrganizationCerebral Spinal FluidCytokinesNon-steroidal anti-inflammatory drugSystemic lupus erythematosusSLElipopolysaccharideCSFselective serotonin reuptake inhibitorsMonoamine oxidase inhibitorsHPAadrenocorticotropic hormonecorticotrophin releasing hormonehypothalamic–pituitary–adrenalpathogen associated molecular patternsCRPProstaglandin E2WHO
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Joshua D. Rosenblat, Danielle S. Cha, Rodrigo B. Mansur, Roger S. McIntyre,